Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease

Primary outcome measure: ADAS-COG (time frame baseline, 2 months, 4 months) Secondary outcome measure: CGI-C,FAB, ADL, Neuropsychological computerized test(time frame baseline, 2 months, 4 months.

Estimated enrollment: 40 patients Estimated Study start Date: November 2008 Estimated Study Completion date: November 2009 Number of arms: 2

Ages: 50-85 Genders: both

Inclusion criteria

• Men and women aged 50-85.
• Diagnosed with Alzheimer's disease for at least one year (by the DSM-IV criteria).
• Scored below 24 on the MMSE.
• Received drug therapy for their disease, with each treatment having been administered at an acceptable dosage for at least 5 weeks, with either no effect or only partial response.
• Answered in the negative to all questions in the pre-TMS treatment safety questionnaire.
• Gave their oral and written consent to participate in the trial.

Exclusion criteria

• An additional neurological or psychiatric disorder.
• Severe personality disorder.
• Uncontrolled hypertension.
• History of epilepsy, seizure, or heat convulsion.
• History of epilepsy or seizure in first degree relatives.
• History of head injury or stroke.
• History of metal implants in the head (except dental fillings).
• History of surgery entailing metallic implants or known history of any metallic particles in the eye, implanted cardiac pacemaker, cochlear implants, use of neurostimulators, or any medical pumps.
• History of migraines in the last six months.
• History of drug or alcohol abuse.
• Inadequate communication with examiner.
• Participation in another clinical study, either concurrent with this trial or in the 3 months preceding it.
• Inability to sign a consent form.